Emcure Pharmaceuticals Limited has informed the Exchange regarding a press release dated November 10, 2025, titled "Novo Nordisk India partners with Emcure Pharma to commercialise Poviztra® in India as a second brand of Wegovy®".
EMCURE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Emcure Pharmaceuticals has announced a partnership with Novo Nordisk India to commercialise Poviztra® in India, which will be marketed as a second brand of Wegovy® (semaglutide). Wegovy® is Novo Nordisk's globally recognised weight-loss and diabetes management drug. Under this arrangement, Emcure will leverage its established Indian distribution and sales network to bring Novo Nordisk's GLP-1 product to Indian patients. The partnership positions Emcure as Novo Nordisk's local commercialisation partner for this high-demand therapy in India. This aligns with the growing obesity and diabetes treatment market in the country.
Positive for Emcure shareholders — association with a marquee global brand like Novo Nordisk and entry into the fast-growing obesity drug segment could drive meaningful future revenue. Stock may see positive sentiment given the commercial upside and brand credibility.